All lobbying filings

T1INTERNATIONAL USA

Lobbying for T1INTERNATIONAL USA

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 8, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Maine

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)

Bills named in this filing 6

S. 1040
Drug Competition Enhancement Act
S. 1041
Affordable Prescriptions for Patients Act
S. 1095
Stop STALLING Act
S. 1096
Preserve Access to Affordable Generics and Biosimilars Act
S. 1269
INSULIN Act of 2023
S. 954
Affordable Insulin Now Act of 2023

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.